ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2026
The potential of molecular testing and mutation analysis for detecting isoniazid and rifampicin-resistant Mycobacterium tuberculosis in Thailand.
Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant tuberculosis (TB) poses a significant threat, and drug-susceptibility testing (DST) is essential for effective TB treatment and control. Genotypic DST has been used for the early detection of drug-resistant TB, and the detection of isoniazid (INH) resistance is increasingly important. This study aims to determine the potential of genotypic DST using the AnyplexTM II MTB/MDR real-time polymerase chain reaction (PCR) kit and analyze the mutations associated with INH and rifampicin (RIF) resistance in Mycobacterium tuberculosis (MTB). DST and DNA sequencing of the katG, inhA, and rpoB genes were performed in 146 MTB isolates. Compared with phenotypic DST, the Anyplex real-time PCR assay showed the sensitivity of 84.0%, 83.3%, 85.7%, and 94.6%; and the specificity of 96.9%, 96.4%, 98.2%, and 92.3% for the detection of INH resistance, RIF resistance, multidrug-resistant TB (MDR-TB), and drug-susceptible MTB, respectively. Substantial agreement with DNA sequencing was observed. For INH resistance, 91.8% had mutations in the katG or inhA; the katG gene accounted for 71.8%, and the inhA promoter region accounted for 20.0%. S315T was predominant in the katG mutation, and only C(-15)T was present in the inhA mutation. For RIF resistance, 95.1% harbored the rpoB mutation, with S531L and D516V being the two most common. The association of mutations with INH and RIF resistance was high. The study highlighted the significance of data on the genetic determinants of INH and RIF resistance, and suggested the potential of using genotypic DST, such as the Anyplex II MTB/MDR assay, in the country and similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.